The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...
FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
New prostate cancer drug showing ‘remarkable’ results during clinical trial - The new drug, known as VIR-5500, uses a ...
Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...
The average age of men who get diagnosed is 67.
A drug for advanced prostate cancer has shown “remarkable” results in an early-stage trial, with patients who had previously ...
Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...
In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...
Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...
Stockhead on MSN
Health Check: Telix jumps first hurdle with its advanced prostate cancer therapy trial
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...
A new drug for advanced prostate cancer has shown promise in early trials experts have said, with the medication shrinking tumors in some patients. Prostate cancer is the most common cancer among men ...
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results